Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Health Network, Toronto
With
Crohn's and Colitis Foundation
To maintain site/extent of disease and medication consistent among groups, the design is a double blind crossover placebo-controlled trial.
1. If mild anaemia, patients are randomized to 300 mg of ferrous fumarate or placebo for 4 weeks followed by 2 weeks of washout period after which patients will crossover the opposite treatments for another 4 weeks.
2. If moderate anaemia, patients will receive 600 mg of ferrous fumarate for 10 weeks. They are randomized to either vitamin E (800 IU) or placebo for 4 weeks followed by 2 weeks of washout period after which patients will crossover the opposite treatments for another 4 weeks
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\> 18 years old
diagnosed with inflammatory Bowel Disease (ulcerative colitis and Crohn's disease)
with mild or moderate anaemia
You may not be if
not diagnosed with bowel obstruction
not diagnosed with short bowel syndrome
not taking iron supplement or antioxidant vitamins and minerals